Scholar Rock (NASDAQ:SRRK) Price Target Raised to $58.00

Scholar Rock (NASDAQ:SRRK) had its target price hoisted by Piper Sandler from $51.00 to $58.00 in a research report report published on Wednesday morning, Marketbeat reports. Piper Sandler currently has an overweight rating on the stock.

A number of other equities research analysts have also recently commented on the company. BMO Capital Markets reissued an “outperform” rating and issued a $50.00 target price on shares of Scholar Rock in a research note on Friday, November 14th. Barclays lifted their price target on Scholar Rock from $52.00 to $53.00 and gave the stock an “overweight” rating in a research report on Tuesday. UBS Group started coverage on shares of Scholar Rock in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price target on the stock. Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday. Finally, HC Wainwright restated a “buy” rating and set a $58.00 price objective on shares of Scholar Rock in a research note on Tuesday. Four investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $54.14.

Scholar Rock Stock Performance

Shares of SRRK opened at $45.29 on Wednesday. The company has a quick ratio of 6.30, a current ratio of 6.95 and a debt-to-equity ratio of 0.41. The stock has a market cap of $5.20 billion, a P/E ratio of -13.20 and a beta of 0.70. The business’s 50 day moving average price is $45.32 and its 200-day moving average price is $39.28. Scholar Rock has a 52 week low of $22.71 and a 52 week high of $49.82.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same period in the prior year, the business posted ($0.64) EPS. Equities research analysts anticipate that Scholar Rock will post -2.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, General Counsel Junlin Ho sold 9,580 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total value of $445,757.40. Following the completion of the transaction, the general counsel owned 241,545 shares in the company, valued at $11,239,088.85. The trade was a 3.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Caryn Parlavecchio sold 9,035 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total value of $420,398.55. Following the transaction, the insider directly owned 169,087 shares in the company, valued at approximately $7,867,618.11. The trade was a 5.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 208,470 shares of company stock worth $9,201,778 in the last 90 days. 13.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Scholar Rock

A number of hedge funds have recently bought and sold shares of SRRK. Siren L.L.C. lifted its stake in Scholar Rock by 17.0% during the 4th quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock valued at $476,842,000 after acquiring an additional 1,575,008 shares during the period. Wellington Management Group LLP grew its stake in shares of Scholar Rock by 26.7% in the fourth quarter. Wellington Management Group LLP now owns 5,759,428 shares of the company’s stock worth $253,703,000 after acquiring an additional 1,213,541 shares during the period. Vanguard Group Inc. raised its holdings in shares of Scholar Rock by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 5,195,465 shares of the company’s stock valued at $228,860,000 after purchasing an additional 280,538 shares during the last quarter. State Street Corp lifted its position in Scholar Rock by 7.2% during the fourth quarter. State Street Corp now owns 4,034,434 shares of the company’s stock valued at $177,717,000 after purchasing an additional 271,331 shares during the period. Finally, Orbis Allan Gray Ltd lifted its position in Scholar Rock by 1,034.5% during the fourth quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock valued at $151,044,000 after purchasing an additional 3,126,677 shares during the period. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Key Headlines Impacting Scholar Rock

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: FDA & commercial progress for apitegromab creates a clear commercial pathway and longer‑term revenue upside, a material catalyst for the stock. Scholar Rock outlines 2026 apitegromab BLA resubmission and commercial launch following FDA progress
• Positive Sentiment: Recent quarterly results beat consensus (EPS of -$0.76 vs. -$0.86) and triggered a large volume spike, evidence of investor interest and potential momentum. Scholar Rock (NASDAQ:SRRK) Sees Large Volume Increase After Strong Earnings
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $58 price target while raising several medium‑ and long‑term EPS forecasts (FY2027–FY2030), signaling continued analyst conviction in the company’s longer‑term outlook. Scholar Rock (NASDAQ:SRRK) Earns “Buy” Rating from HC Wainwright
• Neutral Sentiment: HC Wainwright made a mix of small upward revisions to several quarterly estimates (Q1–Q3 2026) but these are modest improvements and mostly reflect modeling tweaks rather than changed guidance from the company.
• Negative Sentiment: HC Wainwright lowered FY2026 and Q4‑2026 EPS estimates (Q4 2026 from -$0.64 to -$0.82; FY2026 to -$3.55 from -$3.45), increasing near‑term uncertainty and likely contributing to selling pressure despite the long‑term upgrades.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).